AstraZeneca licenses novel antidepressant compounds discovered by Mayo Clinic, Virginia Tech collaboration
| dc.contributor.author | Trulove, Susan | en |
| dc.coverage.spatial | Blacksburg, Va. | en |
| dc.date.accessioned | 2015-10-29T21:36:02Z | en |
| dc.date.available | 2015-10-29T21:36:02Z | en |
| dc.date.issued | 2009-02-09 | en |
| dc.description.abstract | AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds. | en |
| dc.format.mimetype | text/html | en |
| dc.identifier.uri | http://hdl.handle.net/10919/62570 | en |
| dc.publisher | Virginia Tech. University Relations | en |
| dc.rights | In Copyright | en |
| dc.rights.holder | Virginia Tech. University Relations | en |
| dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | en |
| dc.subject | Research | en |
| dc.title | AstraZeneca licenses novel antidepressant compounds discovered by Mayo Clinic, Virginia Tech collaboration | en |
| dc.type | Press release | en |
| dc.type.dcmitype | Text | en |
Files
Original bundle
1 - 1 of 1